Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS)
CNY 8.22
(-1.56%)
CNY 8.22
(-1.56%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 327.5 Million CNY | 3.82% |
| 2022 | 312.87 Million CNY | -51.12% |
| 2021 | 628.7 Million CNY | 21.38% |
| 2020 | 524.48 Million CNY | 19.85% |
| 2019 | 417 Million CNY | 59.82% |
| 2018 | 270.66 Million CNY | 28.86% |
| 2017 | 211.99 Million CNY | 12.32% |
| 2016 | 189.84 Million CNY | -0.64% |
| 2015 | 188 Million CNY | 15.34% |
| 2014 | 162.78 Million CNY | 13.06% |
| 2013 | 144.94 Million CNY | 40.92% |
| 2012 | 102.86 Million CNY | -11.29% |
| 2011 | 115.62 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 84.66 Million CNY | -13.26% |
| 2024 Q3 | 8.95 Million CNY | -89.97% |
| 2024 Q1 | 52.28 Million CNY | 26.87% |
| 2023 Q3 | 39.95 Million CNY | -9.58% |
| 2023 Q4 | 64.63 Million CNY | 61.75% |
| 2023 FY | - CNY | 3.82% |
| 2023 Q1 | 38.88 Million CNY | -32.89% |
| 2023 Q2 | 44.19 Million CNY | 13.66% |
| 2022 Q4 | 57.94 Million CNY | 303.38% |
| 2022 Q3 | -28.48 Million CNY | -309.46% |
| 2022 Q2 | 13.6 Million CNY | -87.57% |
| 2022 Q1 | 109.37 Million CNY | -22.08% |
| 2022 FY | - CNY | -51.12% |
| 2021 Q3 | 101.02 Million CNY | -29.14% |
| 2021 FY | - CNY | 21.38% |
| 2021 Q1 | 101.08 Million CNY | 23.92% |
| 2021 Q2 | 142.57 Million CNY | 41.05% |
| 2021 Q4 | 140.37 Million CNY | 38.95% |
| 2020 Q1 | 82.56 Million CNY | 21.44% |
| 2020 Q3 | 89.51 Million CNY | -39.27% |
| 2020 FY | - CNY | 19.85% |
| 2020 Q2 | 147.4 Million CNY | 78.53% |
| 2020 Q4 | 81.57 Million CNY | -8.87% |
| 2019 Q2 | 91.24 Million CNY | 34.6% |
| 2019 FY | - CNY | 59.82% |
| 2019 Q4 | 67.99 Million CNY | -31.81% |
| 2019 Q3 | 99.7 Million CNY | 9.27% |
| 2019 Q1 | 67.79 Million CNY | 60.18% |
| 2018 Q2 | 61.48 Million CNY | 36.95% |
| 2018 Q1 | 44.89 Million CNY | 100.71% |
| 2018 FY | - CNY | 28.86% |
| 2018 Q4 | 42.32 Million CNY | -1.4% |
| 2018 Q3 | 42.92 Million CNY | -30.18% |
| 2017 FY | - CNY | 12.32% |
| 2017 Q2 | 40.46 Million CNY | -16.52% |
| 2017 Q3 | 28.03 Million CNY | -30.72% |
| 2017 Q4 | 22.36 Million CNY | -20.21% |
| 2017 Q1 | 48.47 Million CNY | 66.95% |
| 2016 Q3 | 22.67 Million CNY | -26.79% |
| 2016 Q2 | 30.97 Million CNY | -25.46% |
| 2016 Q4 | 29.03 Million CNY | 28.05% |
| 2016 FY | - CNY | -0.64% |
| 2016 Q1 | 41.55 Million CNY | -11.22% |
| 2015 Q1 | 57.34 Million CNY | 14.34% |
| 2015 FY | - CNY | 15.34% |
| 2015 Q4 | 46.8 Million CNY | 56.66% |
| 2015 Q3 | 29.87 Million CNY | -0.51% |
| 2015 Q2 | 30.03 Million CNY | -47.63% |
| 2014 Q4 | 50.15 Million CNY | 0.0% |
| 2014 FY | - CNY | 13.06% |
| 2013 FY | - CNY | 40.92% |
| 2012 FY | - CNY | -11.29% |
| 2011 FY | - CNY | 0.0% |